Cancer Cell

Article	Citations
TAMing immunity through an unexpected source	3325
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture	613
A snapshot of the earliest stages of hepatocellular carcinoma	554
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression	528
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	512
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	490
Diet-microbiome interactions in cancer	466
Lymphoma accelerates T cell and tissue aging	459
Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions	434
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity	432
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	405
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	389
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	358
Spatial profiling technologies illuminate the tumor microenvironment	349
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	340
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	319
Accelerated approvals: Early-phase success or premature authorization?	312
Long-range cholinergic input promotes glioblastoma progression	310
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	308
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth	297
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	289
KIT as a therapeutic target in neuroendocrine prostate cancer	288
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	286
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	285
B cell heterogeneity in cancer comes of age	276

Cancer vaccines	264
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	251
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	243
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma	237
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	231
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	231
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	230
Challenges in neoantigen-directed therapeutics	229
T cell dynamism and immune-related adverse events	221
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	218
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression	213
The aging lung microenvironment awakens melanoma metastases	211
When the methylome becomes the microscope	211
Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS	210
A holistic view of cancer	210
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	206
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	204
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	204
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	199
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	196
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	195
High endothelial venules in cancer: Regulation, function, and therapeutic implication	195
Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses	194
A genetic portrait of metastatic seeds in lung adenocarcinoma	193
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression	190
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	188
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	186
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	186
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	185
Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas	180
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	180
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	177
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	177
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer	176
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	174
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	174
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	172
Challenges and opportunities for modeling aging and cancer	172
Immunosensitivity cuts across mismatch repair status in colorectal cancer	171
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	165
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	164
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	164
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	163
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	161
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	161
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	161
Targeting STING to generate therapeutic anti-tumor immunity	157
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	157
Circulating tumor DNA as a biomarker in early phase clinical trials	155
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	153

A conserved, terminal, pro-tumor neutrophil population	153
Ubiquitin control of cytosolic DNA sets immune responses to DNA damage	153
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	151
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program	150
Knowledge-enhanced pretraining for vision-language pathology foundation model on cancer diagnosis	147
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	145
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	145
Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression	144
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	144
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	143
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	143
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	143
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	142
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	141
Integrated proteogenomic characterization of glioblastoma evolution	141
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	139
Immune determinants of the pre-metastatic niche	135
Tumor-infiltrating lymphocytes: A new hope	134
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	131
GDF15 research from bench to bedside	131
Tumors on different wavelengths	130
The winner takes it all: Competition drives clonal selection in gliomagenesis	129
A circular RNA in neuroendocrine carcinomas	129
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	128
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	125
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	125
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	123
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest	123
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	122
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies	121
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	121
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma	120
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	120
New horizons at the interface of artificial intelligence and translational cancer research	119
Proteogenomic data and resources for pan-cancer analysis	118
Firing up neutrophil anti-tumor immunity with cocktails	117
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1 resistance mutation in NSCLC: The first-in-human phase 1 trial	114
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	110
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	108
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	108
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	108
Hidden spark: From cold to hot in BRAF colorectal cancer	107
When blood mutations turn beneficial	106
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	106
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	105
Cellular senescence in precancer lesions and early-stage cancers	105
Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance	104
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	103
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	102
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	101
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer	101
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	101
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	101
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	99
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	99
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	99
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models	99
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	98
Plasma cell and cancer stem cell crosstalk in glioblastoma	96
Stromal barriers to the abscopal effect	96
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	95
Engineering myeloid cells for cancer immunotherapy	95
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	95
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	94
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	94
Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01	94
Tumor microbiome links cellular programs and immunity in pancreatic cancer	93
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study	92
Macrophages: Targets for next-generation cancer immunotherapy	91
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	91
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	90
Stromal lipid species dictate melanoma metastasis and tropism	89
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	88
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	88
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	88
When immunotherapy meets surgery in non-small cell lung cancer	87
A first-in-class EGFR-directed KRAS G12V selective inhibitor	87
When essential metal elements become culprits—Cuproptosis in focus	86
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	86
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	85

A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	85
B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity	85
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence	84
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak	82
Genomic mapping of metastatic organotropism in lung adenocarcinoma	82
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth	82
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	81
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	80
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	79
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors	79
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	78
Subclonal immune evasion in non-small cell lung cancer	77
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity	77
Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications	76
Spatial patterns of glioblastoma	75
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	74
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	74
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	74
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	73
Identification of specific PP2A complexes involved in human cell transformation	73
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	73
Vascular characterization reveals immunomodulatory targets for brain metastases	73
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma	73
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	73
Rethinking immune states in brain metastasis	71
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	71
Immune memory shapes ovarian cancer recurrence	71
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	71
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	71
The coming era of nudge drugs for cancer	70
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	69
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	69
Sex and cancer immunotherapy: Current understanding and challenges	69
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	68
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	68
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	68
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	68
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	68
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	67
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	67
Neutrophil-activating therapy for the treatment of cancer	67
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	67
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma	67
Rethinking relief: Targeting sensory neurons to combat cancer and pain	65
Engineered natural killer cells for cancer therapy	65
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	64
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	63
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	63
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis	63
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	63
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors	62
Senescent alveolar macrophages promote early-stage lung tumorigenesis	62
Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer	62
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	61
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors	61
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	60
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	60
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	60
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	60
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	59
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	58
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	58
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	57
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	57
Cooperative CAR targeting to selectively eliminate AML and minimize escape	57
The importance of ancestry to understanding tumor mutation burden in cancer	56
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer	56
Leading medulloblastoma to a differentiation end	56
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases	56
Probing cancer with small-molecule tools—Progress and challenges	56
Integrating priorities at the intersection of cancer and neuroscience	55
Cancer cell death: Cell-autonomous and immunogenic dimensions	55
Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer	54
Precision medicine in AML: Function plus -omics is better than either alone	54
Tumor-reactive T helper cells in the context of vaccination against glioma	54
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy	54
Of HIFs and hERVs: Neoantigen generation in kidney cancer	54
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches	54
Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity	54
Disarming myeloid resistance in CAR T therapy	54
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells	53
Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy	53
Spatial transcriptomics	53
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	52
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer	52
Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma	52
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors	52
The temporal progression of lung immune remodeling during breast cancer metastasis	52
Biomimetic models in radiotherapy research: An essential bridge between bench and beam	51
Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer	51
Envision the future of precision medicine in pediatric cancer	51
T cell-eosinophil crosstalk—A new road for effective immune checkpoint blockade in breast cancer?	51
NKG2A blocks the anti-metastatic functions of natural killer cells	51
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	50
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer	50